Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy

Paolo Andrea Zucali, Tommaso De Pas, Giovannella Palmieri, +21

Journal of Clinical Oncology

Cancer ManagementThymic Carcinoma PreviouslyImmunologyPathologyPhase Ii Study +18

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Christopher P. Vellano, Michael G. White, Miles C. Andrews, +62

Nature

Hormonal ReceptorBreast CancerPharmacotherapyEndocrinologyMedicine +4

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone, +44

European Journal of Cancer

Advanced CancerMedicineImmune Checkpoint InhibitorsImmunologyPathology +7

Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

Fabio Conforti, Laura Pala, Eleonora Pagan, +25

Clinical Cancer Research

Metaplastic breast cancer: Prognostic and therapeutic considerations

Giovanni Corso, Samuele Frassoni, Antonia Girardi, +14

Journal of Surgical Oncology

Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study

Olga Nigro, Graziella Pinotti, Federica De Galitiis, +48

European Journal of Cancer

Cancer ImmunosurveillanceAutoimmune DiseaseMedicineMulticentre StudyImmunology +10

PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors

Anna Teresa Alberobello, Yisong Wang, Frans Beerkens, +8

Journal of Thoracic Oncology

Potential Therapeutic TargetTumor BiologyMedicineReceptor Tyrosine KinasePathology +6

Sex and cancer immunotherapy: Current understanding and challenges

Laura Pala, Tommaso De Pas, Chiara Catania, +6

Cancer Cell

Tumor ImmunologyCancer ImmunosurveillanceImmunologyTumor ImmunityImmune Checkpoint Inhibitor +5

Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial

Fabio Conforti, Paolo Andrea Zucali, Laura Pala, +16

The Lancet Oncology

MedicineImmunologyPathologyImmune Checkpoint InhibitorAnti-cancer Agent +4

Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors

Fabio Conforti, Xu Zhang, Guanhua Rao, +10

Cancer Research